Our clinical trials unit will start a new phase I trial in patients with early Parkinson’s disease. Patients will be included in different cohorts, single dose and ascending doses, in patients with or without mutations in the LRRK2 gene, by means of an intrathecal administration of an antisense oligonucleotide. Only 62 patients will participate in 17 centers in different countries, including our site, Hospital Universitari General de Catalunya.

Compartir:

No dude en llamarnos        1-+34 935 656 000